Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service structural heart (TAVR, TEER) cases in Kentucky: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 39 | 566 | 37% |
| 2020 | 40 | 655 | 41% |
| 2021 | 49 | 784 | 47% |
| 2022 | 41 | 678 | 52% |
| 2023 | 45 | 693 | 55% |
| 2024 | 40 | 718 | 57% |
| 2025 from claims | – | 732 592–859 | 58% |
| 2026 forecast | – | 768 601–964 | 59% |
| 2027 forecast | – | 807 598–1,067 | 60% |
| 2028 forecast | – | 848 600–1,171 | 60% |
| 2029 forecast | – | 891 606–1,278 | 61% |
| 2030 forecast | – | 936 613–1,389 | 62% |
Transcatheter aortic valve replacement and mitral edge-to-edge repair. Professional codes (what the surgeon bills): CPT 33361, 33362, 33363, 33364, 33365, 33366, 33418, 33419; the hospital bills MS-DRG 266, 267.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 46% of the cases CMS names in Kentucky; 25 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 217 | 4,689+3.4%/yr | +3.4%/yr | 1.7 | 0% | 6,380 in 2030+5.3%/yr |
| Texas | 191 | 3,813+6.2%/yr | +6.2%/yr | 1.5 | 0% | 6,400 in 2030+9%/yr |
| Virginia | 70 | 2,001+4.7%/yr | +4.7%/yr | 1.7 | 0% | 2,460 in 2030+3.5%/yr |
| Tennessee | 67 | 1,854+4.5%/yr | +4.5%/yr | 2.2 | 0% | 2,680 in 2030+6.3%/yr |
| Georgia | 72 | 1,794+2.7%/yr | +2.7%/yr | 1.7 | 0% | 2,890 in 2030+8.3%/yr |
| North Carolina | 75 | 1,460−1.4%/yr | −1.4%/yr | 1.2 | 0% | 2,070 in 2030+6%/yr |
| South Carolina | 56 | 1,406+10%/yr | +10%/yr | 1.8 | 0% | 2,380 in 2030+9.2%/yr |
| Maryland | 45 | 1,095+6.5%/yr | +6.5%/yr | 1.1 | 0% | 1,750 in 2030+8.1%/yr |
| Oklahoma | 38 | 772+1.6%/yr | +1.6%/yr | 1.4 | 0% | 1,030 in 2030+4.9%/yr |
| Alabama | 44 | 739−2.6%/yr | −2.6%/yr | 1.4 | 0% | 660 in 2030−1.9%/yr |
| Louisiana | 50 | 724+2.7%/yr | +2.7%/yr | 1.5 | 0% | 940 in 2030+4.5%/yr |
| Arkansas | 31 | 553+0.7%/yr | +0.7%/yr | 1.3 | 0% | 420 in 2030−4.4%/yr |
| Mississippi | 30 | 446+8%/yr | +8%/yr | 1.0 | 0% | 590 in 2030+4.9%/yr |
| Delaware | 16 | 290+19%/yr | +19%/yr | 1.5 | 0% | 520 in 2030+10%/yr |
| District of Columbia | 8 | 271−1.1%/yr | −1.1%/yr | 3.8 | 0% | 310 in 2030+2.3%/yr |
| West Virginia | 12 | 269+1.5%/yr | +1.5%/yr | 1.1 | 0% | 460 in 2030+9.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 96 | 3,828−8.3%/yr | −8.3%/yr | 6.71.1× | 0% | 3,340 in 2030−2.2%/yr |
| Mechanical circulatory support | 0 | 264−6.4%/yr | −6.4%/yr | 0.61.0× | 0% | 220 in 2030−2.9%/yr |
Structural heart (TAVR, TEER) in every state, and its device makers · Every procedure market in Kentucky · Every state · Compare with Florida
Abbott leads with 73% of company spending on these surgeons in 2025, +58 pts on 2024.
In 2025, 5 companies reported engagement with Kentucky’s surgeons worth $463K in consulting, speaking, meals and travel tied to these products, about $12K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 52 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.